Longterm Survival Benefit Of Neoadjuvant Liposomal Doxorubicin, Docetaxel, And Trastuzumab In Her2-Overexpressing Breast Cancer: A Retrospective And Multicenter Analysis.

e12653Background: Concurrent therapy of trastuzumab, anthracycline and taxane for the neoadjuvant treatment of breast cancer (BC) resulted in an improved rate of pathological complete response (pCR). We have previously shown that concomitant chemotherapy with liposomal doxorubicin and Docetaxel in combination with trastuzumab resulted in high pCR rates in HER2-positive breast cancer. At the same time the combination showed acceptable toxicities and low cardiac events. In this follow-up of a retrospective analysis we report data on disease-free und overall survival. Methods: 83 patients were treated in 3 oncologic centers in Austria. All of them received neoadjuvant liposomal doxorubicin (50 - 60 mg/m²), docetaxel (75 mg/m²) and trastuzumab over the course of 6 cycles for HER2 positive stage I-III breast cancer. None of these patients showed cardiovascular disease and had a left ventricular ejection fraction (LVEF) ≥ 55% at baseline. All patients underwent surgery after neoadjuvant chemotherapy. Median fol...